Abstract | OBJECTIVE: The objective of this study was to evaluate patterns of recurrence and prognostic factors as well as the role of adjuvant chemotherapy in stage II-IV ovarian SBT. METHODS: We performed a retrospective review of all patients with advanced-stage SBT treated at our institution from 1979 to 2008. Advanced stage was defined as FIGO stage II-IV. Progression-free survival (PFS) was defined as the time of diagnosis to time of recurrence/death or last follow-up. Kaplan-Meier method was used to report the PFS rate. RESULTS: A total of 80 stage II-IV patients were identified, of which 15 (19%) were stage II, 63 (79%) were stage III, and 2 (2.5%) were stage IV. The site of metastasis was pelvis in 15 patients (19%), omentum in 29 patients (36%), isolated lymph nodes in 2 patients (2.5%), lung in 1 patient (1%), axilla in 1 patient (1%), and multiple sites in 32 patients (40%). With a median follow-up of 4.8 years, 17 patients (21%) developed recurrent disease. Only patients with metastasis to the omentum or multiple sites developed recurrent disease. Of the 65 stage III/IV patients, 17 patients (26%) received adjuvant chemotherapy following diagnosis. The 3-year progression-free survival (PFS) was 89.9% (95% CI, 77.3-95.7) for patients who did not receive adjuvant chemotherapy compared with 70.6% (95% CI, 43.1-86.6) for patients who received adjuvant chemotherapy. CONCLUSIONS: While advanced-stage ovarian SBT generally has a good prognosis, nearly 21% of patients develop recurrent disease with intermediate follow-up. It is unclear from these data if adjuvant chemotherapy influenced PFS.
|
Authors | Karin K Shih, Qin C Zhou, Carol Aghajanian, Jae Huh, Robert A Soslow, Jessica C Morgan, Alexia Iasonos, Dennis S Chi, Richard R Barakat, Nadeem R Abu-Rustum |
Journal | Gynecologic oncology
(Gynecol Oncol)
Vol. 119
Issue 2
Pg. 270-3
(Nov 2010)
ISSN: 1095-6859 [Electronic] United States |
PMID | 20719369
(Publication Type: Journal Article)
|
Copyright | Copyright © 2010 Elsevier Inc. All rights reserved. |
Topics |
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Chemotherapy, Adjuvant
- Cystadenocarcinoma, Serous
(drug therapy, pathology, surgery)
- Disease-Free Survival
- Female
- Humans
- Middle Aged
- Neoplasm Metastasis
- Neoplasm Recurrence, Local
(pathology)
- Neoplasm Staging
- Ovarian Neoplasms
(drug therapy, pathology, surgery)
- Retrospective Studies
- Young Adult
|